Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65

Citizens analyst Silvan Turkcan has maintained a Market Outperform rating on Exelixis (NASDAQ: EXEL) and raised the price target from $55 to $65. This adjustment reflects a positive outlook on the company's performance in the market.